Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Merck (MRK) Presents Data from VYTORIN Exploratory Analysis
March 16, 2015 3:35 PM EDTMerck (NYSE: MRK) announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. The new analysis shows that VYTORIN (ezetimibe/simvastatin) which combines simvastatin with the non-statin ZETIA® (ezetimibe) reduced total (defined as initial and recurrent) cardiovascular events by 9% compared to simvastatin alone (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007; by treatment group, 4,562 vs. 4,983 total events, respectively). These data were presented as part of this afternoons late-breaking featured clinical research session at the 2015 American College of Cardiology Scientific Sessions.
The results on the... More
Merck (MRK) Announces Cancellation of FDA Committee Meeting for Sugammadex Injection NDA Review
March 13, 2015 4:03 PM EDTMerck (NYSE: MRK) said it was informed today that the U.S. Food and Drug Administration (FDA) has cancelled the meeting of the Anesthetic and Analgesic Drug Products Advisory Committee scheduled for March 18, 2015. The committee had planned to discuss the resubmission of the New Drug... More
